Main points of investment

Indapamide: high performance-to-price ratio, significant brand effect.

The company is a brand general medicine-based enterprises, the main varieties of "Shoubishan" brand indapamide film clothing tablets, "Sanyu" brand male treasure capsule, "Meifu" brand itraconazole capsule and so on. There are a large number of people with hypertension in our country, and the state has introduced a plan for the prevention and treatment of chronic diseases, so there is much room for improvement in the antihypertensive drug market. Indapamide tablet is a diuretic, which has the best antihypertensive effect in the same drug, and the product is cheap, so it is suitable for primary medical institutions to use in the national base drug list. The introduction of generic drug quality consistency evaluation is conducive to the improvement of general drug concentration, and the share of brand general medicine will be expanded.

Biochemical pharmaceuticals: implement large variety marketing strategy and enter into the field of vaccine.

Biochemical pharmaceuticals mainly produce hormone and heparin preparations, contributing to almost all injection business revenue. Hydrocortisone succinate is the exclusive variety of biochemical pharmaceuticals, creating a blank in the production of non-antibiotic aseptic drugs by spray drying technology. Began to enter the field of vaccines, the current construction of 23-valent pneumococcal polysaccharide vaccine production base.

With the integration of group chemical resources, the effect of M & An is obvious.

Lisheng Pharmaceutical is positioned as the chemical pharmaceutical integration platform of Tianjin Pharmaceutical Group. It has acquired a 100% stake in Central Pharmaceutical this year. In the future, Jinkang Pharmaceutical will gradually inject the drug approval of candesartan axetil into the company. In the future, the product structure will be mainly cardiovascular drugs and antibiotics.